ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Comparative Effectiveness of Vonoprazan Dosing Strategies in Bismuth-Based Quadruple Therapy for Helicobacter pylori Eradication: A Prospective Non-inferiority Cohort Study.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of a reduced-drug burden quadruple therapy with vonoprazan, cefuroxime, minocycline, and bismuth forFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Vonoprazan 20 mg twice daily is effective for Helicobacter pylori (H.pylori) eradication, but studies on the efficacy of 20 mg once daily are limited. The efficacy, tolerability, and cost-effectiveness of bismuth-based quadruple therapy with vonoprazan 20 mg once daily were evaluated for H. pylori eradication. Materials and Methods: A prospective cohort study was conducted at TaiZhou Hospital of Zhejiang Province between January and September 2024. Participants were divided into 2 groups: low-dose vonoprazan (QD, 20 mg once daily) and standard-dose vonoprazan (BID, 20 mg twice daily). The remaining drugs (colloidal bismuth pectin, clarithromycin, and amoxicillin) were the same for both groups, with a treatment duration of 14 days. Urea breath tests were performed 6-8 weeks post treatment. Results: In the intention-to-treat analysis, eradication rates were 89.2% (91/102) in the QD group and 88.9% (88/99) in the BID group, with no significant difference (P = .941). In the per-protocol (PP) analysis, eradication rates were 92.2% (83/90) in the QD group and 95.2% (79/83) in the BID group, also without a significant difference (P = .426). The incidence of adverse events was 8.9% in the QD group and 12.0% in the BID group (P = .497), respectively. The cost-effectiveness ratios were 2.59 for the QD group and 3.96 for the BID group in the PP analysis, respectively. Conclusion: Vonoprazan 20 mg once daily showed comparable efficacy to twice-daily dosing as part of a bismuth-based quadruple regimen for H. pylori eradication, with better cost-effectiveness, making it a promising option, especially in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.